Trial subgroup analyses support the use of either allopurinol or febuxostat in patients with stage 3 CKD and gout. A prespecified analysis of the STOP-GOUT trial revealed that allopurinol has similar ...
With each 150-mg dose increase of allopurinol, patients with gout who had low fractional excretion of urate achieved a greater reduction in serum urate. Allopurinol appears to have a more pronounced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results